Biolatam conference slated for Nov. 29-30 in San Juan
The third edition of Biolatam international life science partnering conference will take place in San Juan Nov. 29-30, organizers announced Wednesday.
The event, produced by EBD Group and ASEBIO in collaboration with Puerto Rico Science, Technology & Research Trust, will bring more than 300 life science dealmakers from pharma, biotech and service companies representing U.S., Latin American and European entities to Puerto Rico.
Attendees include executives from innovative biotech companies from across Latin America, representing a variety of areas such as health, agrifood, industrials, plus emerging medical device and digital technology companies. Leaders of industry and academia as well as the investment community representing venture capital firms, private equity, and angels will be part of the event as well.
“There is a growing wave of interest in partnerships with Latin American biopharma companies. The success of Biolatam is the response to this interest. The global and regional company executives who attend are eager to connect and gain prime access to this emerging market,” said Anna Chrisman, group managing director, EBD Group.
From dealmaking and alliance management to unique financing opportunities, the Biolatam program is designed to equip decision makers with information on the business opportunities in the Latin American market.
“The commitment of the Puerto Rico Government to innovation, and the country’s political and legal stability, its rich biodiversity, as well as the economic strength of many biotechnology-dependent sectors such as foodstuffs, cosmetics, and energy, make Puerto Rico an ideal venue to celebrate Biolatam,” said Ion Arocena, general director of ASEBIO.
“ASEBIO and EBD Group are working with Latin American partners to promote business development opportunities in this region. Puerto Rico has an excellent geostrategic position and is a gateway to the U.S., the world’s largest biotech market,” he said.
Featured speakers at Biolatam 2016 include: Ion Arocena, managing director at ASEBIO; Abel Baerga-Ortiz, director, Center for Tropical Biodiversity and Bioprospecting at the Science Trust; Rolando Castro, CEO at Cognitiva IBM Watson Strategic Partner; Gabriela Couto, president of the Costa Rican Biotech and Medical Device Association; Lucy Crespo, CEO at the Science Trust; Carmen Cuevas-Marchante, director, Research and Development at PharmaMar; Kosmas Krestos, executive director at Puerto Rico Consortium for Clinical Investigation; Iván Lugo-Montes, executive director, INDUNIV Research Consortium; and Andrew Sandford, VP, global business development, Biologics, Catalent Biologics.